Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
2005 1
2011 1
2012 1
2013 1
2014 3
2015 3
2016 1
2017 5
2018 2
2020 2
2021 2
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
RT-CMR Imaging for Noninvasive Characterization of HFpEF: Medium-Term Outcomes of the HFpEF Stress Trial.
Backhaus SJ, Rösel SF, Schulz A, Lange T, Hellenkamp K, Gertz RJ, Wachter R, Steinmetz M, Kutty S, Raaz U, Friede T, Seidler T, Uecker M, Hasenfuß G, Schuster A. Backhaus SJ, et al. Among authors: rosel sf. JACC Cardiovasc Imaging. 2022 May;15(5):943-945. doi: 10.1016/j.jcmg.2021.11.013. Epub 2022 Jan 12. JACC Cardiovasc Imaging. 2022. PMID: 35512961 Free article. No abstract available.
Left-atrial long-axis shortening allows effective quantification of atrial function and optimized risk prediction following acute myocardial infarction.
Backhaus SJ, Rösel SF, Stiermaier T, Schmidt-Rimpler J, Evertz R, Schulz A, Lange T, Kowallick JT, Kutty S, Bigalke B, Gutberlet M, Hasenfuß G, Thiele H, Eitel I, Schuster A. Backhaus SJ, et al. Among authors: rosel sf. Eur Heart J Open. 2022 Aug 12;2(5):oeac053. doi: 10.1093/ehjopen/oeac053. eCollection 2022 Sep. Eur Heart J Open. 2022. PMID: 36268539 Free PMC article.
High-risk additional chromosomal abnormalities at low blast counts herald death by CML.
Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, Kohlbrenner K, Haferlach C, Schlegelberger B, Fabarius A, Seifarth W, Spieß B, Wuchter P, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Burchert A, Brümmendorf TH, Hasford J, Hochhaus A, Saußele S, Baccarani M; SAKK and the German CML Study Group. Hehlmann R, et al. Leukemia. 2020 Aug;34(8):2074-2086. doi: 10.1038/s41375-020-0826-9. Epub 2020 May 7. Leukemia. 2020. PMID: 32382082 Free PMC article.
Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial.
Coombes RC, Tovey H, Kilburn L, Mansi J, Palmieri C, Bartlett J, Hicks J, Makris A, Evans A, Loibl S, Denkert C, Murray E, Grieve R, Coleman R, Borley A, Schmidt M, Rautenberg B, Kunze CA, Rhein U, Mehta K, Mousa K, Dibble T, Lu XL, von Minckwitz G, Bliss JM; Randomized European Celecoxib Trial (REACT) Trial Management Group and Investigators. Coombes RC, et al. JAMA Oncol. 2021 Sep 1;7(9):1291-1301. doi: 10.1001/jamaoncol.2021.2193. JAMA Oncol. 2021. PMID: 34264305 Free PMC article. Clinical Trial.
Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML.
Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, Kohlbrenner K, Haferlach C, Schlegelberger B, Fabarius A, Seifarth W, Spieß B, Wuchter P, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Burchert A, Brümmendorf TH, Hasford J, Hochhaus A, Saußele S, Baccarani M; SAKK and the German CML Study Group. Hehlmann R, et al. Leukemia. 2020 Oct;34(10):2823. doi: 10.1038/s41375-020-01039-7. Leukemia. 2020. PMID: 32913312 Free PMC article.
24 results